Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various bioph…
Biotechnology
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 754.10 | -253.62 | 29.69 | |
| Graham Fair Price | -90.23 | 1.86 | 19.08 | |
| PEG | 66222.83 | -7.09 | 0.01 | |
| Price/Book | 7.37 | 2.06 | 1.92 | |
| Price/Cash Flow | -58.78 | 22.99 | -55.76 | |
| Prices/Earnings | 10963.49 | 701.85 | 6.34 | |
| Price/Sales | 12.21 | 23.62 | 21.05 | |
| Price/FCF | -58.78 | 22.99 | -55.76 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Bad
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -96.84 | -0.03 | 0.87 | |
| Operating Margin | -87.37 | -0.13 | 1.03 | |
| ROA | -99.02 | < 0.005 | 0.03 | |
| ROE | 0.08 | < 0.005 | -99.03 | |
| ROIC | 0.03 | < 0.005 | -80.45 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | < 0.005 | -0.07 | |
| Dividends QOQ | < 0.005 | 0.05 | 10334.66 | |
| EBIT QOQ | 3.05 | -1.12 | -63.24 | |
| EPS QOQ | 5.94 | -0.99 | -83.32 | |
| FCF QOQ | -2.84 | 3.59 | 26.63 | |
| Revenue QOQ | 0.11 | -0.05 | -57.75 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 117.04 | 108.18 | -7.57 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.48 | 0.49 | 0.25 | |
| Quick Ratio | 7.87 | 12.48 | 58.53 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 14.61 | 14.49 | -0.87 | |
| Cash | 1.11 | 1.94 | 75.25 | |
| Capex | -2.24 | -0.19 | 91.45 | |
| Free Cash Flow | -0.50 | 1.30 | 158.21 | |
| Revenue | 1.33 | 1.27 | -5.14 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad